| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:833-839.)
© 2007 American Heart Association, Inc.
Cardiovascular Disease in Women |
From PSE Paris-Jourdan Sciences Economiques (LÉcole des Hautes Études en Sciences Sociales, École Normale Supérieure, École Nationale des Ponts et Chaussées, Centre National de la Recherche Scientifique), Paris, France (C.M.); University of Paris-Dauphine, Paris, France, and the Institute of Health Economics and Management, Lausanne, Switzerland (B.D.); AP-HP, Henri Mondor Hospital, Department of Public Health, Paris, France (I.D.-Z.); and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Department of Cardiology, Paris, France (P.G.S.).
Correspondence to Carine Milcent, PhD, PSE-ENS Bât A, 48 Boulevard Jourdan, 75014 Paris. E-mail milcent{at}pse.ens.fr
Received September 25, 2006; accepted January 3, 2007.
| Abstract |
|---|
|
|
|---|
Methods and Results All hospital admissions in France with a discharge diagnosis of acute myocardial infarction were extracted from the national payment database. Logistic regression on mortality was performed for age, comorbidities, and coronary interventions. Nonparametric microsimulation models estimated the percutaneous coronary intervention and mortality rates that women would experience if they were "treated like men." Data were analyzed from 74 389 patients hospitalized with acute myocardial infarction, 30.0% of whom were women. Women were older (75 versus 63 years of age; P<0.001) and had a higher rate of hospital mortality (14.8% versus 6.1%; P<0.0001) than men. Percutaneous coronary interventions were more frequent in men (7.4% versus 4.8%; 24.4% versus 14.2% with stent; P<0.001). Mortality adjusted for age and comorbidities was higher in women (P<0.001), with an excess adjusted absolute mortality of 1.95%. Simulation models related 0.46% of this excess to reduced use of procedures. Survival benefit related to percutaneous coronary intervention was lower among women.
Conclusions The difference in mortality rate between men and women with acute myocardial infarction is due largely to the different age structure of these populations. However, age-adjusted hospital mortality was higher for women and was associated with a lower rate of percutaneous coronary intervention. Simulations suggest that women would derive benefit from more frequent use of percutaneous coronary intervention, although these procedures appear less protective in women than in men.
Key Words: angioplasty epidemiology mortality myocardial infarction revascularization sex women
| Introduction |
|---|
|
|
|---|
Editorial p 823
Clinical Perspective p 839
Thus, although it is agreed that the age-adjusted mortality rate after acute myocardial infarction is higher in women than in men, uncertainty remains about whether this finding is related to differences in baseline risk or in management (particularly the use of revascularization) and whether the latter is related to gender bias (the Yentl syndrome20) or to differences in eligibility for aggressive therapies or patient preferences.21
The aims of the present study were to compare age-adjusted, gender-specific hospital mortality rates for patients hospitalized for acute myocardial infarction and to determine whether mortality variations could be explained by gender 1differences in epidemiology, in patterns of use of percutaneous coronary intervention (PCI), or in the benefit of PCI.
| Methods |
|---|
|
|
|---|
Records for acute myocardial infarction were analyzed to exclude coding errors.22 The process of ensuring an inclusive and clean dataset and obtaining administrative clearance for access to individual patient data required
5 years, which explains the lag between the time the dataset was obtained and the analysis. Demographic data, primary and secondary diagnoses, and procedural and immediate outcome data were extracted. Information on outcomes after discharge was not available.
Study Variables and Outcome
Demographic variables included gender and age. Comorbid conditions were captured by secondary diagnoses: heart failure, valvular disease, conduction disease, diabetes mellitus, severe hypertension, renal insufficiency, stroke, and peripheral arterial disease. Procedural data included those related to cardiac catheterization, percutaneous coronary angioplasty, and stenting. The outcome variable was death during the index admission. For the sake of simplicity, and because PCI is rarely performed without stenting, PCI with stenting was considered representative of coronary interventions.
Statistical Methods
Categorical data are presented as percentages with absolute numbers. Logistic regressions were performed to test for gender differences in mortality and use of coronary interventions in each age group. Odds ratios are reported, and Wald tests and 95% confidence intervals (CIs) are provided to check for the significance of differences between proportions. Multivariable logistic regressions were performed to adjust for differences in age, comorbidities, and intervention rates.
A series of microsimulation models were developed in the spirit of the Oaxaca decomposition, creating a hypothetical set of events (procedures and outcomes) for the population.2326
The first simulation predicted the probability of PCI and death, depending on gender, comorbidities, and use of PCI, and the death rate of women if they were "treated like men." This simulation assessed gender differences resulting from variation in treatment while controlling for gender differences in age and comorbidities (see the Appendix in the online Data Supplement). We hypothesized that the only difference between men and women was the decision to use invasive procedures, and we computed the probability of death of women if they were treated like men of the same age with similar comorbidities. Each woman was attributed the age- and comorbidity-specific probability of PCI plus stent obtained from the male population. We then computed whether this "men-like" procedure rate resulted in reduced mortality in women. The second simulation tested the hypothesis that the outcome of PCI would differ according to gender, resulting in a higher death rate.27 The model was built for PCI plus stent.
All tests were 2 sided, and values of P<0.05 were considered statistically significant. All analyses were performed with the StataSE 8 software and SAS statistical package (SAS version 8.2, SAS Inc, Cary, NC).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
Use of Interventional Procedures
During the index admission, men were more likely to undergo coronary angiography and intervention than were women; this observation was consistent across all age groups (P<0.001) (Table 2). Overall, the ratio of interventions to total coronary angiography was higher in men than in women, although this difference was heterogeneous with respect to age; in patients <75 years of age, angiography more frequently led to PCI in men than in women, whereas the converse was true in patients >75 years of age (Table 2).
|
Hospital Mortality
The crude hospital mortality rate was higher for women than for men (14.8% versus 6.1%; P<0.0001). The odds ratio for crude mortality rates was 2.65 (95% CI, 2.52 to 2.79). This 8.64% difference was due mainly to gender differences in the age distribution. After adjustment for age (using the age distribution of women as reference), the absolute gender difference in mortality was 1.95%. Across age categories, crude mortality and mortality adjusted for comorbidities were consistently higher among women (Table 3).
|
The use of coronary interventions was associated with a lower mortality rate after adjustment for age and comorbidities (P<0.01) (Figure 1). After adjustment for comorbidities and the use of interventions, the mortality rate remained consistently and significantly higher for women than for men in each age category except patients >85 years of age (P=0.08) (Figure 2). The type of hospital to which patients were admitted and the volume of acute myocardial infarctions treated per hospital had no impact on gender differences in mortality (data not shown).
|
|
Simulations
The 1.95% age-adjusted gender difference in mortality rate was explored further by simulations to determine its relation to gender differences in the use of coronary interventions, outcome of procedures, and impact of comorbidities.
Simulated Rates of PCI Plus Stent
In the first simulation, an expected rate of PCI plus stenting for women was computed by using the probability of men with the same age and comorbidities (Table 5). The expected simulated rate of PCI plus stenting in women was 17.5% compared with observed rates of 14.2% in women and 24.4% in men. Therefore, approximately one third of the observed difference in the use of PCI plus stenting appeared to be related to gender disparity, and two thirds appeared to be related to age and comorbidities.
|
Simulated Rates of Mortality
The relationship of reduced provision of PCI to the 1.95% gender gap in mortality (14.78% in women versus 12.83% age adjusted in men; Table 5) was explored in the second simulation, which computed "expected" mortality rates in women with 2 models (Table 4). Model 1 computed the expected probability of death of women if they had experienced the hospital rates of PCI plus stent of men of a similar age. Overall, this expected mortality rate would be 14.32%, thus accounting for 0.46% (relative percentage, 23.6%) of the age-adjusted 1.95% gender gap. Model 2 allowed for possible gender differences in the impact of comorbidities and PCI plus stent on mortality rate by computing the expected probability of death of women if they had similar rates of coronary interventions but also a similar response to PCI and comorbidities to that of men. The expected mortality rate in women calculated by this method would be 12.55% instead of 14.78%, accounting for 1.77% (relative percentage, 90.8%) of the 1.95% gender gap.
|
Thus, of the 8.64-point crude excess mortality in women with acute myocardial infarction, 6.69 is explained by the age structure of the population, 0.46 by the difference in procedure rates, and 1.77 by gender differences in the outcome of procedures and the impact of comorbidities (Table 5). The residual (0.28) is related to differences in other characteristics (including unobservable characteristics). Thus, one quarter of the gender gap appears to be related to differential use of PCI plus stent between men and women.
The potential impact of increasing intervention rates in women (by following the same decision rules as for men) is illustrated in Figure 3, which displays the distributions of the observed age-adjusted mortality and the expected mortality in women. Age-adjusted mortality rate would be reduced (shifted to the left) across the entire risk distribution if rates of interventions were the same in women and men.
|
| Discussion |
|---|
|
|
|---|
This finding provides a rationale for implementing measures to ensure optimal provision of coronary interventions in women experiencing myocardial infarction. In addition, the simulations indicate that more liberal use of PCIs in women would likely result in consistent benefit across all risk strata. An additional finding from the simulations was that the use of PCI in women may be associated with a reduced benefit compared with that in men, possibly because of anatomic or biological differences.
Underuse of invasive procedures in women with acute myocardial infarction has been reported previously, although the independent relationship between gender and worse outcomes is still debated.28 There is recent evidence from the United States that, despite widespread debate about the gender gap, sex differences in the provision of therapies in acute myocardial infarction have remained unchanged.29 However, in that analysis, gender differences in the provision of therapeutic interventions and in outcomes were less marked than in the present study and were largely influenced by the appropriateness of procedures.30
The issue of less aggressive treatment resulting in a higher mortality rate in women was raised as early as 1991 by Healy.20 The present simulations indicate that, even if women were treated just like men, some excess mortality would remain. The explanation for the reduced protective effect against death afforded by PCI in women is unclear. It may be related to generally poorer outcomes of PCI in women (less benefit and higher complication rates), possibly because of smaller target-vessel size, increased vessel tortuosity, and other biological differences. Indeed, previous analyses have found that women had an excess risk of death or myocardial infarction in the early post-PCI period as compared with men,31 particularly when interventions are attempted in an unstable setting32 (although these differences pertained mostly to women undergoing coronary artery bypass grafting), but that these differences appear to abate over time.31
The impact of lower revascularization rates in women on mortality rate strengthens the case for better dissemination and implementation of guidelines for acute myocardial infarction treatment in women.33
Study Limitations
This analysis is subject to several limitations. The database included all forms of acute myocardial infarction, regardless of delay to presentation, presence of ST-segment elevation, and eligibility for reperfusion therapy, because myocardial infarction was defined by ICD-9 coding. No data were collected on ethnicity because French law explicitly prohibits the collection of such variables and detailed information on medication use, including the use of fibrinolysis. In addition, our analysis pertains to all indications for PCI during the index admission but does not allow us to explore which procedures were done as primary PCI rather than elective PCI or to assess the appropriateness of the indications, a factor that has been linked to gender differences in use of procedures.30 In that respect, it is important to acknowledge that no information is available in our dataset on the angiographic features in men and women. Nevertheless, there may be important gender differences in vessel size, tortuosity, and general eligibility for PCI that may translate into differences in the use of PCI (such as women having smaller diseased vessels, which could account for the lower ratio of PCI to angiography in women than in men [54% versus 58%]).
This analysis pertains to a dataset that is 7 years old, and some changes in practice have taken place over this period that are related mainly to more frequent use of primary PCI. However, it is uncertain whether these changes have been unbalanced across gender. This analysis relied on a discharge database to document comorbidities; therefore, only a limited amount of information was available, and potential confounder variables may have been missed. Although the prospective payment system creates an incentive to record exhaustively secondary diagnoses and procedures, its use to finance French hospitals has so far been limited, resulting in potential underreporting. Because comorbid conditions affect women more frequently than men (particularly with regard to peripheral arterial disease, which tends to be underdiagnosed in women), underreporting of comorbidities may result in an artificial underestimation of the gender gap. The simulations used to estimate expected rates of reperfusion or hospital mortality in women if they were treated like men are subject to caution because medical organizational factors such as delayed diagnosis are not accounted for. Finally, outcomes were assessed at discharge, and previous analyses31 have suggested that gender differences in early outcomes may become attenuated over a longer follow-up. Overall, this type of simulation may simplify a series of complex variables involved in patient care; thus, the estimates of the effect of each therapy may be imprecise.
The strength of our findings lies in the size of the population and the use of microsimulation analyses. The latter have been introduced in econometric models that compare salaries in men and women and were recently extended to other economic fields such as health-econometric studies. To the best of our knowledge, they have not been used yet in the analysis of healthcare delivery.
| Acknowledgments |
|---|
Disclosures
Dr Durand-Zaleski has been a consultant and a speaker for Sanofi-Aventis, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Smith & Nephew, and Boston Scientific. Dr Steg has been a consultant or speaker for AstraZeneca, Bristol-Myers Squibb, Boeringer Ingelheim, GlaxoSmithKline, Medtronic, Merck Sharp & Dohme, Nycomed, Pfizer, Sanofi-Aventis, Schering-Plough, Servier, Takeda, The Medicines Company, and ZLB-Behring. The other authors report no conflicts.
| References |
|---|
|
|
|---|
| Footnotes |
|---|
The online-only Data Supplement, consisting of expanded Methods, is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.664979/DC1.
This article has been cited by other articles:
![]() |
R. Matyal Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review Anesth. Analg., July 1, 2008; 107(1): 37 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Verheugt, C. S.P.M. Uiterwaal, E. T. van der Velde, F. J. Meijboom, P. G. Pieper, H. W. Vliegen, A. P.J. van Dijk, B. J. Bouma, D. E. Grobbee, and B. J.M. Mulder Gender and Outcome in Adult Congenital Heart Disease Circulation, July 1, 2008; 118(1): 26 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Wilson and G. Raveendran What's good for the gander is now good for the goose. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2321 - 2322. [Full Text] [PDF] |
||||
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369. [Full Text] [PDF] |
||||
![]() |
A. Parolari, L. Dainese, M. Naliato, G. Polvani, C. Loardi, M. Trezzi, M. Fusari, C. Beverini, E. Tremoli, P. Biglioli, et al. Do Women Currently Receive the Same Standard of Care in Coronary Artery Bypass Graft Procedures as Men? A Propensity Analysis Ann. Thorac. Surg., March 1, 2008; 85(3): 885 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Anderson and C. J. Pepine Gender Differences in the Treatment for Acute Myocardial Infarction: Bias or Biology? Circulation, February 20, 2007; 115(7): 823 - 826. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |